Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.

摘要: We conducted a prospective evaluation of somatostatin receptor scintigraphy (SRS) for the diagnosis recurrent vesicular or papillary thyroid carcinoma in 16 patients with no detectable iodine uptake. SRS was performed 1, 4 and 24 h after intravenous injection 137–200 MBq indium-111 pentetreotide. Results were interpreted terms assumed presence tumoral tissue: there three true-positives (19%), one false-positive (6%) 12 false-negatives (75%). The true-positive had multiple lesions visible on computerized tomography. negative all high thyroglobulin level alone. In addition, we analyzed consequences interpretative criteria expression variability positivity as well risk false-positives. conclude that when uptake cannot be demonstrated suspected recurrence differentiated carcinoma, would not appear to contribute diagnosis, commonly used tumours density may too restrictive low density.